Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13872894 | 0.92 | ELANE (0.83) | ELANECYP2C9CYP3A4 | |
| SCHEMBL8217872 | 0.92 | ELANE (0.83) | ELANECYP2C9CYP3A4 | |
| SCHEMBL2678247 | 0.91 | ELANE (0.84) | ELANECYP2C9CYP3A4 | |
| SCHEMBL2677742 | 0.88 | ELANE (0.73) | ELANECYP2C9CYP3A4 | |
| SCHEMBL14760482 | 0.88 | ELANE (0.70) | ELANECYP2C9CYP3A4MEN1KMT2A | |
| SCHEMBL2678551 | 0.88 | ELANE (0.70) | ELANECYP2C9CYP3A4MEN1KMT2A | |
| SCHEMBL8281837 | 0.87 | ELANE (0.77) | ELANECYP2C9CYP3A4 | |
| SCHEMBL2679151 | 0.86 | ELANE (0.70) | ELANECYP2C9CYP3A4 | |
| SCHEMBL18204106 | 0.86 | ELANE (0.70) | ELANECYP2C9CYP3A4 | |
| SCHEMBL4547757 | 0.86 | ELANE (0.70) | ELANECYP2C9CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766366-B1 | TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES AS HUMAN NEUTROPHIL ELASTASE INHBITORS | CHIESI FARMA SPA (IT) | 2016-11-09 | — | — | EP | disclosed |
| US-9023855-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-05-05 | — | — | US | disclosed |
| US-9023855-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-05-05 | — | — | US | disclosed |
| US-20140179714-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-26 | — | — | US | disclosed |
| US-20140179714-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-26 | — | — | US | disclosed |
| WO-2013037809-A1 | TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-21 | — | — | WO | disclosed |
| US-20130065913-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-14 | — | — | US | disclosed |
| US-20130065913-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065913-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | ELANE 2/4885CYP2C9 2139/4885CYP3A4 1766/4885 |
| US-20140179714-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | ELANE 2/4885CYP2C9 2135/4885CYP3A4 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.